Showing results (291-300 of 320) with videos related to

Sort By:
Pageof 32
Oncotarget|June 8, 2018
Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives cancer cell resistance to destruxinsDaniela Heilos, Clemens Röhrl, Christine Pirker, et al.
NPJ Vaccines|January 24, 2020
Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factorsFriedrich Erhart, Matthias Hackl, Hannes Hahne, et al.
Acta Neuropathologica Communications|August 9, 2019
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF<sup>V600E</sup>/TERT promoter double-mutated gliomaLisa Gabler, Daniela Lötsch, Dominik Kirchhofer, et al.
Angewandte Chemie (International Ed. in English)|May 27, 2017
An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For PlectinSamuel M Meier, Dominique Kreutz, Lilli Winter, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 4, 2025
A recurrent missense variant in the PPIB gene encoding peptidylprolyl isomerase B underlies adult-onset autosomal dominant optic atrophyKatharina Valentin, Monika Kustermann, Mona R Schneider, et al.
European Urology|April 8, 2022
Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active CompoundIris E Ertl, Ursula Lemberger, Dafina Ilijazi, et al.
Cancer Research|January 9, 2020
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid FeaturesMiriam Marqués, Robin Tranchant, Blanca Risa-Ebrí, et al.
Oncoimmunology|July 3, 2015
Myeloid <i>STAT3</i> promotes formation of colitis-associated colorectal cancer in micePaulina Pathria, Dagmar Gotthardt, Michaela Prchal-Murphy, et al.
EMBO Molecular Medicine|February 6, 2023
A whole-genome scan for Artemisinin cytotoxicity reveals a novel therapy for human brain tumorsJasmin Taubenschmid-Stowers, Michael Orthofer, Anna Laemmerer, et al.
American Journal of Respiratory and Critical Care Medicine|September 5, 2014
Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapyKarin Schelch, Mir A Hoda, Thomas Klikovits, et al.
Pageof 32